Study to Evaluate the Safety and Immunogenicity of an HIV-1 Vaccine Regimen of Adjuvanted UVAX-1107 Followed by Adjuvanted UVAX-1107 or Adjuvanted UVAX-1197 in Healthy Subjects Aged 25-55 Years.

Clinical trial NCT06541093 · COMPLETED

Trial details

NCT number: NCT06541093
Sponsor: Uvax Bio LLC
Status: COMPLETED
Phase: Early Phase 1
Study type: INTERVENTIONAL

AIDS/HIV - RelatedDisease Associated With AIDS Vaccine-Preventable Diseases HIV Infections

Start date: 2024-01-30
Primary completion: 2025-03-21
Enrollment: 34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.